亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy

来那度胺 慢性淋巴细胞白血病 抗原 CD8型 癌症研究 CD5型 免疫疗法 T细胞 免疫系统 免疫学 医学 白血病 多发性骨髓瘤
作者
Annika Nelde,Daniel J. Kowalewski,Linus Backert,Heiko Schuster,Lothar Kanz,Helmut R. Salih,Hans‐Georg Rammensee,Stefan Stevanović,Juliane S. Walz
出处
期刊:Blood [Elsevier BV]
卷期号:128 (22): 3234-3234 被引量:3
标识
DOI:10.1182/blood.v128.22.3234.3234
摘要

Abstract Several studies have proven the positive immunomodulatory effect of lenalidomide, a second-generation derivative of thalidomide, on T-cell responses in CLL, in particular regarding the repair of the immune synapse between CLL and T cells (e.g., Ramsay et al. J Clin Invest 2008), as well as the upregulation of costimulatory molecules on CLL cells (e.g., Aue et al. Haematologica 2009). Therefore, lenalidomide seems to be a promising combination partner for T-cell based immunotherapy approaches in CLL patients. We recently conducted a study which directly characterized the antigenic landscape of CLL by mass spectrometric analysis of naturally presented HLA ligands and identified a panel of CLL-specific CD4+ as well as CD8+ T-cell epitopes as suitable targets for T-cell based immunotherapy (Kowalewski et al. PNAS2015). As anti-cancer drugs can have marked effects on the HLA ligandome of tumor cells, it is of great importance to thoroughly characterize and take into account the effects of the immune modulator lenalidomide not only on the effector cells, but also on the antigenic landscape of the target cells. Here we present a mass spectrometry-based study which longitudinally maps the HLA-presented immunopeptidome and in particular the CLL-associated antigens of primary CLL cells under in vitro lenalidomide treatment. We quantified HLA surface expression on primary CLL cells and autologous B cells (n=4) at t0, t24h and t48h after incubation with 0.5 µM lenalidomide. With regard to HLA class I expression on CD19+CD5+ CLL cells, no significant impact of lenalidomide was observed (fold-change 0.92-1.02, t48h), whereas a slight but also not significant increase of HLA class II molecules after treatment was detectable (fold-change 1.25-1.43, t48h) with absolute molecule counts ranging from 40,000-125,000 class I and 30,000-200,000 class II molecules/cell. Furthermore, we could show that CD19+CD5+ CLL cells (n=4) showed a significantly increased expression of HLA class I molecules compared to normal CD19+CD5-B cells. Implementing label-free quantification, we then assessed HLA class I ligand presentation during in vitro lenalidomide incubation. We observed a higher plasticity of the HLA ligandome over time compared to treatment with lenalidomide. 2.5±3.0% of HLA class I ligands showed significant modulation (fold change ≥4, p≤0.01) after 24h of mock treatment, whereas only 0.9±1.2% of the ligands were modulated upon lenalidomide treatment. At t48hsimilar proportions of modulation were observed with 4.0±1.7% of HLA ligands significantly altered in their abundance over time (mock control), while lenalidomide treatment only resulted in 0.9±1.2% modulated ligands. Out of the 6,991 different HLA class I ligands representing 3,983 source proteins identified on primary CLL cells (n=3) by mass spectrometry, we were able to detect 36 (30.5%) of the HLA-matched CLL-associated epitopes described in previous studies on these three samples. Importantly, these CLL-associated antigens showed robust presentation on CLL cells under in vitro lenalidomide treatment. In order to investigate the impact of lenalidomide-treatment on HLA class I allotype distribution within the ligandome, we analyzed the overall frequencies of HLA allotype restrictions of ligands on treated versus untreated primary CLL cells. Thereby, no changes in the HLA allotype distribution were observed. Analysis of the HLA class II ligandome of primary CLL cells (n=3) revealed a total of 12,026 unique peptides representing 2,333 source proteins. We were able to detect 133 (28.5%) of CLL-associated class II epitopes described in previous studies. Notably, most of the CLL-associated antigens showed robust presentation under lenalidomide therapy. Exemplarily for one patient, we identified 7/66 (10.6%) CLL-associated antigens modulated after 24 h of in vitro lenalidomide treatment, but 10/66 (15.2%) antigens altered over time (mock control). Taken together our study provides direct insights into the impact of lenalidomide on the HLA ligandome of primary CLL cells. We were able to show that in vitro lenalidomide has no relevant influence on, and rather seems to stabilize the HLA-presented immunopeptidome of primary CLL cells. Importantly, CLL-associated epitopes are stably presented under lenalidomide treatment. Therefore, lenalidomide appears to be an ideal combination partner for T-cell based immunotherapy in CLL patients. Disclosures Kowalewski: Immatics Biotechnologies GmbH: Employment. Schuster:Immatics Biotechnologies GmbH: Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
sugar发布了新的文献求助10
2秒前
科目三的应助被sugar采纳,获得10
9秒前
18秒前
FIGGIEKIO发布了新的文献求助10
25秒前
30秒前
科研通AI65的应助被冰凌采纳,获得10
31秒前
大模型的应助被甜甜的小土豆采纳,获得10
32秒前
39秒前
41秒前
可爱的函函的应助被专注凌柏采纳,获得10
41秒前
黄志伟完成签到,获得积分20
42秒前
黄志伟发布了新的文献求助10
45秒前
万能图书馆的应助被冰凌采纳,获得10
47秒前
超帅的半莲完成签到,获得积分10
50秒前
52秒前
Caiyuping完成签到 ,获得积分10
54秒前
星辰大海的应助被花痴的文涛采纳,获得10
55秒前
魔幻芷巧发布了新的文献求助10
56秒前
ay完成签到 ,获得积分10
56秒前
科研通AI6.3的应助被冰凌采纳,获得10
57秒前
58秒前
smsk完成签到,获得积分20
58秒前
1分钟前
wanci的应助被科研通管家采纳,获得10
1分钟前
执着的秋柳完成签到,获得积分10
1分钟前
Orange的应助被科研通管家采纳,获得10
1分钟前
gAle完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
iuiu666完成签到 ,获得积分10
1分钟前
1分钟前
hudaojiadecaigou完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195028
求助须知:如何正确求助?哪些是违规求助? 9580770
关于积分的说明 21872653
捐赠科研通 7794788
什么是DOI,文献DOI怎么找? 3437886
关于科研通互助平台的介绍 2561176
邀请新用户注册赠送积分活动 2484562